- Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies1
- Center for Devices and Radiological Health (CDRH) appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff1
- Certificates of confidentiality: guidance for sponsors, sponsor-investigators, researchers, industry, and food and drug administration staff1
- Changes in home health care use in Medicare Advantage compared to traditional Medicare: 2011--20161
- Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs)1
- Civil money penalties relating to the ClinicalTrials.gov data bank: guidance for responsible parties, submitters of certain applications and submissions to FDA, and FDA staff1
- Classification of posterior cervical screw systems: small entity compliance guide : guidance for industry and Food and Drug Administration staff1
- Clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions1
- Clinical investigations for prostate tissue ablation devices: guidance for industry and Food and Drug Administration staff1
- Clinical labs: studies suggest biopsy specimen misidentification and contamination errors are infrequent : report to the Ranking Member, Committee on Finance, U.S. Senate1
- Communication and management challenges impeded HHS's response to the zero-tolerance policy1
- Community-acquired bacterial pneumonia: developing drugs for treatment1
- Comparative effectiveness research: Patient-Centered Outcomes Research Institute and HHS continue activities and plan new efforts : report to Congressional committees1
- Competitive generic therapies1
- Compliance policy for the quantity of bioavailability and bioequivalence samples retained under 21 CFR 320.38(c)1
- Confirmed COVID-19 cases, metropolitan and nonmetropolitan counties1
- Confronting rural America’s health care crisis: BPC Rural Health Task Force policy recommendations1
- Considerations for defining rural places in health policies and programs1
- Consumer Antiseptic Rub Final Rule: questions and answers : small entity compliance guide1
- Controlled correspondence related to generic drug development1